title: Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
abstract: Leukemias arising from immature nature killer (NK) cells have been proposed as distinct entities and are rare. Treatment and prognosis of these diseases are controversial, and data on children are limited. According to the literature, one of these distinct leukemias may be myeloid/NK cell precursor acute leukemia (MNKPL), with the blasts being cytochemically myeloperoxidase negative (MPO(-)) and phenotypically CD56(+)CD3(-)CD7(+)CD34(+) and myeloid antigens(+). The other may be myeloid/NK cell acute leukemia (MNKL), in which the blasts were cytochemically MPO(dim) and phenotypically CD56(+)CD16(-)CD3(-)CD33(+)HLA-DR(-). Between 2005 and 2008, 4 MNKPL and 1 MNKL children aged 1.3 to 12.5 years were encountered in the First Affiliated Hospital of Sun Yat-Sen University. In those with MNKPL, remarkable extramedullary involvement usually occurring in adults was not observed; however, myelofibrosis was found in 2 children. The child with MNKL abandoned treatment. Those with MNKPL were treated with a protocol designed for childhood high-risk acute lymphoblastic leukemia (ALL) containing cytarabine, mitoxantrone, etoposide, l-asparaginase, and methotrexate according to the myeloid and lymphoid characteristics of MNKPL. They responded slowly to chemotherapy and were in complete remission (CR) for 26 to 63 months, except 1 who died in CR from pneumonia. They had longer survival and seemed to have a better outcome than those reported previously. In conclusion, childhood leukemias with immature NK cell markers may have different characteristics from their adult counterparts. A protocol including agents used for acute myeloid leukemia combined with those for ALL is seemingly effective for treatment of MNKPL. However, a modified treatment strategy designed more specifically for MNKPL and longer observations are needed.
authors.affiliation: Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
authors.forename: Xiao-Qing
authors.initials: XQ
authors.lastname: Guan
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Ke
authors.forename: Li-Bin
authors.initials: LB
authors.lastname: Huang
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Zhang
authors.forename: Ying-Chuan
authors.initials: YC
authors.lastname: Zhang
authors.forename: Xue-Qun
authors.initials: XQ
authors.lastname: Luo
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007694:Killer Cells, Natural / Q000473:pathology*; D007945:Leukemia, Lymphoid / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D001215:Asparaginase; D008727:Methotrexate